Clinical Trials
Open
Accrual
0%
SWOG Clinical Trial Number
S1916
Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients
Status Notes
This is being distributed for IRB review only.
Research Committee(s)
Cancer Care Delivery
Activated
06-11-2019
Open
SWOG Clinical Trial Number
CTSU/NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study
Research Committee(s)
Prevention
Leukemia
Activated
06-01-2019
ClinicalTrials.gov Registry Number
NCT02775383
Open
Accrual
1%
SWOG Clinical Trial Number
S1800A
A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)
Status Notes
S1800A will open to accrual May 17, 2019, effective 11:00 am PST.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
05-17-2019
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S1806
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
Research Committee(s)
Genitourinary Cancer
Activated
04-19-2019
Open
SWOG Clinical Trial Number
CTSU/NRG-BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/ Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Status Notes
Activated by NRG: 3/12/19.
Activated by SWOG: 4/1/19.
Activated by SWOG: 4/1/19.
Activated
04-01-2019
ClinicalTrials.gov Registry Number
NCT03199885
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S1714
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Status Notes
This study is active as of 3/1/19.
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Activated
03-01-2019